Takehiro Tozuka

435 total citations
33 papers, 249 citations indexed

About

Takehiro Tozuka is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Takehiro Tozuka has authored 33 papers receiving a total of 249 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Takehiro Tozuka's work include Lung Cancer Treatments and Mutations (18 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Lung Cancer Research Studies (10 papers). Takehiro Tozuka is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Lung Cancer Research Studies (10 papers). Takehiro Tozuka collaborates with scholars based in Japan, United States and Singapore. Takehiro Tozuka's co-authors include Masahiro Seike, Hiroshi Yoshida, Satoru Kitazono, Ken Uchibori, Noriko Yanagitani, Makoto Nishio, Hiroaki Sakamoto, Akihiko Gemma, Tsukasa Hasegawa and Takahiro Yoshizawa and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and BMC Cancer.

In The Last Decade

Takehiro Tozuka

32 papers receiving 243 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Takehiro Tozuka Japan 10 198 156 29 28 23 33 249
Ryota Shibaki Japan 10 243 1.2× 188 1.2× 17 0.6× 32 1.1× 47 2.0× 23 316
Norimitsu Kasahara Japan 10 196 1.0× 163 1.0× 38 1.3× 40 1.4× 26 1.1× 29 301
Grygorii Ursol United Kingdom 4 233 1.2× 143 0.9× 24 0.8× 27 1.0× 54 2.3× 6 268
Masayuki Shirasawa Japan 10 167 0.8× 108 0.7× 21 0.7× 27 1.0× 24 1.0× 25 213
Silvana Acquafredda Italy 6 159 0.8× 94 0.6× 40 1.4× 42 1.5× 43 1.9× 8 237
Farah Louise Lim United Kingdom 4 249 1.3× 159 1.0× 24 0.8× 25 0.9× 56 2.4× 7 287
James Haberberger United States 9 119 0.6× 103 0.7× 50 1.7× 39 1.4× 24 1.0× 18 204
Cornedine J. de Gooijer Netherlands 10 167 0.8× 262 1.7× 23 0.8× 37 1.3× 39 1.7× 27 352
Elisabetta Gambale Italy 8 178 0.9× 116 0.7× 22 0.8× 47 1.7× 40 1.7× 19 246
Margaux Geier France 8 167 0.8× 150 1.0× 17 0.6× 23 0.8× 18 0.8× 41 220

Countries citing papers authored by Takehiro Tozuka

Since Specialization
Citations

This map shows the geographic impact of Takehiro Tozuka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takehiro Tozuka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takehiro Tozuka more than expected).

Fields of papers citing papers by Takehiro Tozuka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takehiro Tozuka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takehiro Tozuka. The network helps show where Takehiro Tozuka may publish in the future.

Co-authorship network of co-authors of Takehiro Tozuka

This figure shows the co-authorship network connecting the top 25 collaborators of Takehiro Tozuka. A scholar is included among the top collaborators of Takehiro Tozuka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takehiro Tozuka. Takehiro Tozuka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tanaka, Hisashi, Tomonori Makiguchi, Takehiro Tozuka, et al.. (2024). Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01. European Journal of Cancer. 213. 115117–115117. 1 indexed citations
2.
Kato, Yasuhiro, Masaru Matsumoto, Kuniko Matsuda, et al.. (2024). Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway. Cancer Medicine. 13(12). e7393–e7393. 1 indexed citations
3.
Tozuka, Takehiro, Yuji Minegishi, Ou Yamaguchi, et al.. (2024). Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060. JTO Clinical and Research Reports. 5(4). 100655–100655. 2 indexed citations
4.
Tozuka, Takehiro, Keisuke Yoshida, Kuniko Matsuda, et al.. (2024). Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer. JTO Clinical and Research Reports. 5(4). 100668–100668. 4 indexed citations
5.
Nakamichi, Shinji, Takehiro Tozuka, Rintaro Noro, et al.. (2023). Successful Treatment with Definitive Concurrent Chemoradiotherapy Followed by Durvalumab Maintenance Therapy in a Patient with Tracheal Adenoid Cystic Carcinoma. Internal Medicine. 62(18). 2731–2735. 4 indexed citations
6.
Miyanaga, Akihiko, Takehiro Tozuka, Yozo Sato, et al.. (2023). Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report. OncoTargets and Therapy. Volume 16. 465–470. 2 indexed citations
7.
8.
9.
Nakamichi, Shinji, Hiroki Iida, Takehiro Tozuka, et al.. (2023). Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report. OncoTargets and Therapy. Volume 16. 65–69. 6 indexed citations
10.
Tozuka, Takehiro, Rintaro Noro, Akihiko Miyanaga, et al.. (2023). Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer. Cancer Medicine. 12(17). 17731–17739. 5 indexed citations
11.
12.
Noro, Rintaro, Shoko Kure, Shinobu Kunugi, et al.. (2022). Acute respiratory failure due to Aspergillus niger infection with acute fibrinous and organazing pneumonia: A case report. Respiratory Medicine Case Reports. 37. 101641–101641. 5 indexed citations
13.
Sakamoto, Hiroaki, Noriko Yanagitani, Takehiro Tozuka, et al.. (2021). Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib. Cancer Reports. 4(6). e1414–e1414. 2 indexed citations
14.
Uchibori, Ken, Takehiro Tozuka, Hiroaki Sakamoto, et al.. (2021). Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2. Thoracic Cancer. 12(6). 906–913. 4 indexed citations
15.
Ariyasu, Ryo, Ken Uchibori, Hironori Ninomiya, et al.. (2020). Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice. Thoracic Cancer. 12(4). 504–511. 15 indexed citations
16.
Tozuka, Takehiro, Satoru Kitazono, Hiroaki Sakamoto, et al.. (2020). Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment. Lung Cancer. 144. 71–75. 22 indexed citations
17.
Tozuka, Takehiro, Masahiro Seike, Yoriko Murata, et al.. (2019). P2.14-41 Risk Factors for Brain Metastasis in Patients with EGFR Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S845–S845. 1 indexed citations
18.
Hasegawa, Tsukasa, Noriko Yanagitani, Hirofumi Utsumi, et al.. (2019). Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer. Anticancer Research. 39(12). 6851–6857. 27 indexed citations
19.
Sugano, Teppei, Masahiro Seike, Rintaro Noro, et al.. (2018). A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab. OncoTargets and Therapy. Volume 11. 5879–5883. 9 indexed citations
20.
Tozuka, Takehiro, Masahiro Seike, Yuji Minegishi, et al.. (2018). Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression. OncoTargets and Therapy. Volume 11. 5601–5605. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ryota Shibaki Breakdown of academic impact, for papers by Norimitsu Kasahara Breakdown of academic impact, for papers by Grygorii Ursol Breakdown of academic impact, for papers by Masayuki Shirasawa Breakdown of academic impact, for papers by Silvana Acquafredda Breakdown of academic impact, for papers by Farah Louise Lim Breakdown of academic impact, for papers by James Haberberger Breakdown of academic impact, for papers by Cornedine J. de Gooijer Breakdown of academic impact, for papers by Elisabetta Gambale Breakdown of academic impact, for papers by Margaux Geier
Rankless by CCL
2026